N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment

N6-methyladenosine (m6A), a pivotal RNA modification, has garnered considerable attention in cell biology and disease research. m6A plays a critical role in the regulation of gene expression, cell proliferation, differentiation, and apoptosis, with particular relevance to the onset and progression of ocular diseases. This review examines the current research on m6A in ocular diseases, including keratitis, cataracts, glaucoma, retinopathy, thyroid ophthalmopathy, and ocular tumors, highlighting its functional significance and potential mechanisms in these conditions. Recent studies suggest that m6A modification influences cellular fate and pathophysiological processes by modulating the expression of key genes. However, a deeper understanding of the precise mechanisms underlying m6A action in ocular diseases is still needed. By synthesizing the existing literature, this review seeks to offer novel insights and identify potential therapeutic targets, thereby advancing clinical applications for ocular disease treatment.

Authors

Institutions

Publication Details

Journal
Cell Death Discovery
Published
2025-11-28
DOI
https://doi.org/10.1038/s41420-025-02867-1
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment

Sizhen Li, Zhongyu Han, Liuzhi Zeng, Jun Wang et al.
Cell Death Discovery
RNA modifications and cancer
article

N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment

Sizhen Li, Zhongyu Han, Liuzhi Zeng, Jun Wang, Yunfeng Zhang, Yating Liu, Chen Xu, L.-J. Liu, Ping Yu, Qiong Yang, Yumeng Lin
article en

Abstract

N6-methyladenosine (m6A), a pivotal RNA modification, has garnered considerable attention in cell biology and disease research. m6A plays a critical role in the regulation of gene expression, cell proliferation, differentiation, and apoptosis, with particular relevance to the onset and progression of ocular diseases. This review examines the current research on m6A in ocular diseases, including keratitis, cataracts, glaucoma, retinopathy, thyroid ophthalmopathy, and ocular tumors, highlighting its functional significance and potential mechanisms in these conditions. Recent studies suggest that m6A modification influences cellular fate and pathophysiological processes by modulating the expression of key genes. However, a deeper understanding of the precise mechanisms underlying m6A action in ocular diseases is still needed. By synthesizing the existing literature, this review seeks to offer novel insights and identify potential therapeutic targets, thereby advancing clinical applications for ocular disease treatment.

Cell Death DiscoveryVol. 12(1)
Tongren Hospital (CN), First Affiliated Hospital of Chengdu Medical College (CN), Southeast University (CN)
Openalex Percentile: Top 66%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment — Sizhen Li, Zhongyu Han, et al. · Cell Death Discovery (2025) | TGRS Research Map | TGRS